Objective Anal cancer is a common cancer among men who have sex with men (MSM); however, there is no standard screening protocol for anal cancer. We conducted a phase II clinical trial to assess the feasibility of teaching MSM to recognise palpable masses in the anal canal which is a common sign of anal cancer in men.
Methods A clinician skilled in performing digital anorectal examinations (DARE) used a pelvic manikin to train 200 MSM, aged 27–78 years, how to do a self-anal examination (SAE) for singles or a partner anal examination (PAE) for couples. The clinician then performed a DARE without immediately disclosing results, after which the man or couple performed an SAE or PAE, respectively. Percentage agreement with the clinician DARE in addition to sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for the SAE, PAE and overall.
Results Men had a median age of 52 years, 42.5% were African American and 60.5% were HIV positive. DARE detected abnormalities in 12 men while the men’s SAE/PAEs detected 9 of these. A total of 93.0% of men classified the health of their anal canal correctly (95% CI 89.5 to 96.5). Overall percentage agreement, sensitivity and specificity were 93.0%, 75.0% and 94.2%, respectively, while PPV and NPV were 45.0% and 98.3%, respectively. The six men who detected the abnormality had nodules/masses ≥3 mm in size. More than half of men (60.5%) reported never checking their anus for an abnormality; however, after performing an SAE/PAE, 93.0% said they would repeat it in the future.
Conclusion These results suggest that tumours of ≥3 mm may be detectable by self or partner palpation among MSM and encourage further investigation given literature suggesting a high cure rate for anal cancer tumours ≤10 mm.
- digital rectal examination
- anal canal
- anus neoplasms
- early detection of cancer
Statistics from Altmetric.com
Handling editor Joseph D Tucker
Contributors AGN, L-YH, MWR and EYC conceptualised the study and formulated the hypotheses. AGN, JTH, NO, MW and SM conducted the investigation. AGN, XZ and SB did the statistical analysis. XZ provided data curation. AGN was responsible for funding acquisition, determining methodology and writing the paper. JTH, L-YH, SB, MW, SM, NO, XZ, ELB, MWR and EYC critically reviewed and edited subsequent drafts.
Funding This work was supported by the National Cancer Institute at the National Institutes of Health [grant number NCI 1R21CA181901-02) to AGN; ClinicalTrials.gov number, NCI-2015-00248]. Publication and report contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCI.
Competing interests The institutions of AGN, JTH, and EYC received NIH grants or subcontracts for the submitted works and/or grants from the NIH outside of the submitted work.
Ethics approval University of Texas Health Sciences Center Committee for the Protection of Human Subjects.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.